https://www.selleckchem.com/pr....oducts/gefitinib-bas
6 95%CI 1.1-2.3; p=0.001), in 2011-2014 (OR 2 95%CI 1.4-2.8; p=0.001), and in 2015-2018 (2.4 95%CI 1.7-3.3; p=0.001) compared to 2002-2006. On the other hand, in females, survival increased from 7% to 18% (p0.001), with a corresponding increase in the odds of survival of almost 3 times from 2002-2006 to 2015-2018 time period (OR 2.9 95%CI 1.5-5.8, p=0.001). No difference in survival probability was observed according to gender when adjusted for age, presenting rhythm, year-groups, OHCA location, EMS arrival time, wi
Tycka om
Kommentar
Dela med sig
